Stay updated with breaking news from Human Use. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Commencement of ONS-5010 NORSE EIGHT clinical trial targeted for first calendar quarter of 2024Company reaffirms potential for European approval for ONS-5010 with Marketing Authorization Application ...
By Chris Wack Cidara Therapeutics shares were up 12% to 83 cents after the company said Rezzayo, or rezafungin acetate, has been approved in the European...
Approval based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and extensive nonclinical development program.REZZAYO...
The stock market has taken investors on a wild ride this year, with plenty of ups and downs along the way. Following an early 2023 surge, stocks witnessed some turbulence as concerns mounted over inflation, rising interest rates, banking turmoil, and escalating geopolitical tensions worldwide.
Mundipharma today announced rezafungin (rezafungin acetate) has been approved in the European Union (EU) for the treatment of invasive candidiasis in adults. The approval by the European Commission (EC) follows the positive opinion of the Committee...